Assertio (ASRT)
(Delayed Data from NSDQ)
$1.16 USD
+0.03 (2.65%)
Updated Oct 17, 2024 04:00 PM ET
After-Market: $1.16 0.00 (0.00%) 7:58 PM ET
4-Sell of 5 4
C Value C Growth B Momentum C VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$1.16 USD
+0.03 (2.65%)
Updated Oct 17, 2024 04:00 PM ET
After-Market: $1.16 0.00 (0.00%) 7:58 PM ET
4-Sell of 5 4
C Value C Growth B Momentum C VGM
Zacks News
Assertio (ASRT) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Assertio (ASRT) delivered earnings and revenue surprises of -100% and 2.51%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
ARS Pharmaceuticals, Inc. (SPRY) Expected to Beat Earnings Estimates: What to Know Ahead of Q2 Release
by Zacks Equity Research
ARS Pharmaceuticals, Inc. (SPRY) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Earnings Preview: Assertio (ASRT) Q2 Earnings Expected to Decline
by Zacks Equity Research
Assertio (ASRT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Revolution Medicines (RVMD) Moves 11.0% Higher: Will This Strength Last?
by Zacks Equity Research
Revolution Medicines (RVMD) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
Assertio (ASRT) Stock Plunges 65% in 3 Months: Here's Why
by Zacks Equity Research
Assertio (ASRT) appears weighed down by the recent leadership transition. The company is also facing challenges with sales of its product franchisee of late.
Assertio (ASRT) Shares Fall as Dan Peisert Steps Down as CEO
by Zacks Equity Research
Assertio (ASRT) appoints Heather Mason as its interim CEO as its current CEO, Dan Peisert, steps down from his role. Shares of the company fall on the same.
Is the Options Market Predicting a Spike in Assertio (ASRT) Stock?
by Sushmita Sarker
Investors need to pay close attention to Assertio (ASRT) stock based on the movements in the options market lately.
Is the Options Market Predicting a Spike in Assertio (ASRT) Stock?
by Zacks Equity Research
Investors need to pay close attention to Assertio (ASRT) stock based on the movements in the options market lately.
Assertio (ASRT) Q2 Earnings Miss Estimates
by Zacks Equity Research
Assertio (ASRT) delivered earnings and revenue surprises of -7.14% and 3.57%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?
Rigel Pharmaceuticals (RIGL) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Rigel (RIGL) delivered earnings and revenue surprises of 50% and 3.34%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?
Aquestive (AQST) to Report Q2 Earnings: What's in Store?
by Zacks Equity Research
Aquestive's (AQST) second-quarter 2023 revenues are likely to have been driven by rising licensed product revenues.
Assertio (ASRT) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
Assertio (ASRT) delivered earnings and revenue surprises of -153.85% and 12.40%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
Assertio (ASRT) Gains But Lags Market: What You Should Know
by Zacks Equity Research
In the latest trading session, Assertio (ASRT) closed at $5.08, marking a +1.6% move from the previous day.
Assertio (ASRT) to Report Q1 Earnings: What's in the Cards?
by Zacks Equity Research
On Assertio Therapeutics' (ASRT) Q1 earnings call, investors will likely focus on the sales performance of its rheumatology, pain and inflammation medicines.
Investors Heavily Search Assertio Holdings, Inc. (ASRT): Here is What You Need to Know
by Zacks Equity Research
Assertio (ASRT) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
Assertio (ASRT) Gains As Market Dips: What You Should Know
by Zacks Equity Research
Assertio (ASRT) closed the most recent trading day at $6.01, moving +1.01% from the previous trading session.
Assertio (ASRT) Gains But Lags Market: What You Should Know
by Zacks Equity Research
In the latest trading session, Assertio (ASRT) closed at $6.30, marking a +0.64% move from the previous day.
Here is What to Know Beyond Why Assertio Holdings, Inc. (ASRT) is a Trending Stock
by Zacks Equity Research
Recently, Zacks.com users have been paying close attention to Assertio (ASRT). This makes it worthwhile to examine what the stock has in store.
Assertio (ASRT) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
Assertio (ASRT) closed at $5.78 in the latest trading session, marking a -0.86% move from the prior day.
Is Trending Stock Assertio Holdings, Inc. (ASRT) a Buy Now?
by Zacks Equity Research
Recently, Zacks.com users have been paying close attention to Assertio (ASRT). This makes it worthwhile to examine what the stock has in store.
Assertio (ASRT) Tops Q4 Earnings and Revenue Estimates
by Zacks Equity Research
Assertio (ASRT) delivered earnings and revenue surprises of 482.61% and 1.58%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
Marinus Pharmaceuticals (MRNS) Reports Q4 Loss, Misses Revenue Estimates
by Zacks Equity Research
Marinus Pharmaceuticals (MRNS) delivered earnings and revenue surprises of 16.48% and 46.22%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
Alaunos (TCRT) to Report Q4 Earnings: What's in the Cards?
by Zacks Equity Research
Alaunos Therapeutics (TCRT) is expected to provide an update on its pipeline candidates, Library TCR-T cell therapy and mbIL-15 TCR-T cell therapy, in its fourth-quarter earnings.
Assertio Holdings, Inc. (ASRT) is Attracting Investor Attention: Here is What You Should Know
by Zacks Equity Research
Assertio (ASRT) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
The Cooper Companies (COO) Q1 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
The Cooper Companies (COO) delivered earnings and revenue surprises of 9.02% and 2.93%, respectively, for the quarter ended January 2023. Do the numbers hold clues to what lies ahead for the stock?